OBJECTIVE: In rheumatoid arthritis (RA), autoreactive B cells are pathogenic drivers and sources of anti-citrullinated protein antibodies (ACPAs) that are a diagnostic biomarker and predictor of worse long-term prognosis. Yet, the immunobiologic significance of persistent ACPA production at the cellular level is poorly understood. This study was undertaken to investigate the representation of ACPA-expressing switched-memory B cells in RA. METHODS: In a cross-sectional study of RA patients, we investigated the presence of continued defects in immune homeostasis as a function of disease activity. Using an enzyme-linked immunosorbent assay (ELISA) and a sensitive multiplex bead-based immunoassay, we characterized fine binding antibody specificities in sera, synovial fluid (SF), and B cell culture supernatants. In this manner, we determined the frequency and epitope reactivity patterns of ACPAs produced by SF B cells and switched-memory blood B cells and compared the latter to serum ACPA levels and disease activity scores. RESULTS: Cultured B cells from SF were shown to spontaneously secrete ACPAs, while constitutive IgG autoantibody production by peripheral blood mononuclear cells (PBMCs) was substantially less frequent. After in vitro stimulation, PBMCs secreted IgG ACPA that was overwhelmingly from switched-memory B cells, across all patient groups treated with methotrexate and/or a tumor necrosis factor inhibitor. Intriguingly, the frequencies of ACPA-expressing switched-memory B cells significantly correlated with serum IgG anti-cyclic citrullinated peptide 3 (r = 0.57, P = 0.003). Moreover, treatment-induced clinical remission had little or no effect on the circulating burden of switched-memory ACPA-expressing B cells, in part explaining the continued dysregulation of humoral immunity. CONCLUSION: Our findings rationalize why therapeutic cessation most often results in disease reactivation and clinical flare. Hence, a clinical disease activity score is not a reliable indicator of the resolution of pathologic recirculating B cell autoimmunity.
OBJECTIVE: In rheumatoid arthritis (RA), autoreactive B cells are pathogenic drivers and sources of anti-citrullinated protein antibodies (ACPAs) that are a diagnostic biomarker and predictor of worse long-term prognosis. Yet, the immunobiologic significance of persistent ACPA production at the cellular level is poorly understood. This study was undertaken to investigate the representation of ACPA-expressing switched-memory B cells in RA. METHODS: In a cross-sectional study of RApatients, we investigated the presence of continued defects in immune homeostasis as a function of disease activity. Using an enzyme-linked immunosorbent assay (ELISA) and a sensitive multiplex bead-based immunoassay, we characterized fine binding antibody specificities in sera, synovial fluid (SF), and B cell culture supernatants. In this manner, we determined the frequency and epitope reactivity patterns of ACPAs produced by SF B cells and switched-memory blood B cells and compared the latter to serum ACPA levels and disease activity scores. RESULTS: Cultured B cells from SF were shown to spontaneously secrete ACPAs, while constitutive IgG autoantibody production by peripheral blood mononuclear cells (PBMCs) was substantially less frequent. After in vitro stimulation, PBMCs secreted IgG ACPA that was overwhelmingly from switched-memory B cells, across all patient groups treated with methotrexate and/or a tumornecrosis factor inhibitor. Intriguingly, the frequencies of ACPA-expressing switched-memory B cells significantly correlated with serum IgG anti-cyclic citrullinated peptide 3 (r = 0.57, P = 0.003). Moreover, treatment-induced clinical remission had little or no effect on the circulating burden of switched-memory ACPA-expressing B cells, in part explaining the continued dysregulation of humoral immunity. CONCLUSION: Our findings rationalize why therapeutic cessation most often results in disease reactivation and clinical flare. Hence, a clinical disease activity score is not a reliable indicator of the resolution of pathologic recirculating B cell autoimmunity.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Yanran Cao; Maja Gordic; Sebastian Kobold; Nesrine Lajmi; Sabrina Meyer; Katrin Bartels; York Hildebrandt; Tim Luetkens; Anna Sophie Ihloff; Nicolaus Kröger; Carsten Bokemeyer; Djordje Atanackovic Journal: J Immunol Methods Date: 2010-03-17 Impact factor: 2.303
Authors: Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Maria F Bellatin; Mei Han; Margarita Fallena; Lin Fan; Donglan Xia; Nancy Olsen; Valerie Branch; David Karp; Peter Stastny Journal: J Immunol Date: 2012-02-15 Impact factor: 5.422
Authors: G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij Journal: J Clin Invest Date: 1998-01-01 Impact factor: 14.808
Authors: Ruth Klaasen; Rogier M Thurlings; Carla A Wijbrandts; Arno W van Kuijk; Dominique Baeten; Danielle M Gerlag; Paul P Tak Journal: Arthritis Rheum Date: 2009-11
Authors: S Dubucquoi; E Solau-Gervais; D Lefranc; L Marguerie; J Sibilia; J Goetz; V Dutoit; A-L Fauchais; E Hachulla; R-M Flipo; L Prin Journal: Ann Rheum Dis Date: 2004-04 Impact factor: 19.103
Authors: Catriona A Wagner; Jeremy Sokolove; Lauren J Lahey; Camilla Bengtsson; Saedis Saevarsdottir; Lars Alfredsson; Michelle Delanoy; Tamsin M Lindstrom; Roger P Walker; Reuven Bromberg; Piyanka E Chandra; Steven R Binder; Lars Klareskog; William H Robinson Journal: Ann Rheum Dis Date: 2013-12-02 Impact factor: 19.103
Authors: Kyle J Bednar; Corwin M Nycholat; Tadimeti S Rao; James C Paulson; Wai-Ping Fung-Leung; Matthew S Macauley Journal: ACS Chem Biol Date: 2019-03-20 Impact factor: 5.100
Authors: Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes Journal: Nat Rev Rheumatol Date: 2018-02-08 Impact factor: 20.543
Authors: Pieter W A Meyer; Mahmood T M Ally; Bridget Hodkinson; Ronald Anderson; Mohammed Tikly Journal: Rheumatol Int Date: 2018-04-30 Impact factor: 2.631
Authors: H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño Journal: Clin Exp Immunol Date: 2021-03-02 Impact factor: 4.330
Authors: Adam J Pelzek; Bo Shopsin; Emily E Radke; Kayan Tam; Beatrix M Ueberheide; David Fenyö; Stuart M Brown; Qianhao Li; Ada Rubin; Yi Fulmer; William K Chiang; David N Hernandez; Hanane El Bannoudi; William E Sause; Alexis Sommerfield; Isaac P Thomsen; Andy O Miller; Victor J Torres; Gregg J Silverman Journal: mBio Date: 2018-03-13 Impact factor: 7.867
Authors: Emma C de Moel; Veerle F A M Derksen; Gerrie Stoeken; Leendert A Trouw; Holger Bang; Robbert J Goekoop; Irene Speyer; Tom W J Huizinga; Cornelia F Allaart; René E M Toes; Diane van der Woude Journal: Arthritis Res Ther Date: 2018-02-26 Impact factor: 5.156
Authors: Emily E Radke; Stuart M Brown; Adam J Pelzek; Yi Fulmer; David N Hernandez; Victor J Torres; Isaac P Thomsen; William K Chiang; Andy O Miller; Bo Shopsin; Gregg J Silverman Journal: Sci Rep Date: 2018-09-05 Impact factor: 4.379